JP2025504859A5 - - Google Patents
Info
- Publication number
- JP2025504859A5 JP2025504859A5 JP2024543097A JP2024543097A JP2025504859A5 JP 2025504859 A5 JP2025504859 A5 JP 2025504859A5 JP 2024543097 A JP2024543097 A JP 2024543097A JP 2024543097 A JP2024543097 A JP 2024543097A JP 2025504859 A5 JP2025504859 A5 JP 2025504859A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- syndrome
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302246P | 2022-01-24 | 2022-01-24 | |
| US63/302,246 | 2022-01-24 | ||
| PCT/IB2023/050504 WO2023139534A1 (en) | 2022-01-24 | 2023-01-20 | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504859A JP2025504859A (ja) | 2025-02-19 |
| JP2025504859A5 true JP2025504859A5 (https=) | 2026-01-27 |
Family
ID=85150566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543097A Pending JP2025504859A (ja) | 2022-01-24 | 2023-01-20 | 補体因子ｂ阻害剤としてのスピロ環式ピペリジニル誘導体及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250115572A1 (https=) |
| EP (1) | EP4469157A1 (https=) |
| JP (1) | JP2025504859A (https=) |
| KR (1) | KR20240138095A (https=) |
| CN (1) | CN118696035A (https=) |
| AU (1) | AU2023209631A1 (https=) |
| CA (1) | CA3247772A1 (https=) |
| CL (1) | CL2024002205A1 (https=) |
| CO (1) | CO2024009660A2 (https=) |
| CR (1) | CR20240300A (https=) |
| DO (1) | DOP2024000142A (https=) |
| IL (1) | IL314186A (https=) |
| JO (1) | JOP20240165A1 (https=) |
| MX (1) | MX2024009062A (https=) |
| PE (1) | PE20242005A1 (https=) |
| WO (1) | WO2023139534A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| IL320661A (en) * | 2022-11-14 | 2025-07-01 | Novartis Pharma Ag | Solid forms of complement factor B inhibitors |
| TW202506657A (zh) * | 2023-04-27 | 2025-02-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種哌啶基吲哚化合物的鹽及其製備方法 |
| CN121889385A (zh) | 2023-07-04 | 2026-04-17 | 希塔拉生物有限公司 | 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物 |
| IL325760A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| AU2024324780A1 (en) * | 2023-08-16 | 2026-02-05 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| TW202543599A (zh) * | 2024-03-08 | 2025-11-16 | 大陸商江蘇豪森藥業集團有限公司 | 一種多元螺環化合物的晶型、其製備方法和醫藥用途 |
| WO2025256600A1 (zh) * | 2024-06-12 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 一种杂环化合物及其用途 |
| WO2026002007A1 (zh) * | 2024-06-25 | 2026-01-02 | 珠海联邦制药股份有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| RS66635B1 (sr) * | 2017-08-31 | 2025-04-30 | Novartis Ag | Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije |
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| CN120081822A (zh) * | 2021-06-03 | 2025-06-03 | 诺瓦提斯药物公司 | 经取代的吲哚化合物及其使用方法 |
| EP4389742A4 (en) * | 2021-08-18 | 2026-01-14 | Xizang Haisco Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE |
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
-
2023
- 2023-01-20 CA CA3247772A patent/CA3247772A1/en active Pending
- 2023-01-20 CR CR20240300A patent/CR20240300A/es unknown
- 2023-01-20 JP JP2024543097A patent/JP2025504859A/ja active Pending
- 2023-01-20 CN CN202380019453.6A patent/CN118696035A/zh active Pending
- 2023-01-20 PE PE2024001666A patent/PE20242005A1/es unknown
- 2023-01-20 AU AU2023209631A patent/AU2023209631A1/en active Pending
- 2023-01-20 EP EP23702675.2A patent/EP4469157A1/en active Pending
- 2023-01-20 WO PCT/IB2023/050504 patent/WO2023139534A1/en not_active Ceased
- 2023-01-20 IL IL314186A patent/IL314186A/en unknown
- 2023-01-20 MX MX2024009062A patent/MX2024009062A/es unknown
- 2023-01-20 US US18/729,949 patent/US20250115572A1/en active Pending
- 2023-01-20 KR KR1020247027601A patent/KR20240138095A/ko active Pending
-
2024
- 2024-07-22 CO CONC2024/0009660A patent/CO2024009660A2/es unknown
- 2024-07-22 CL CL2024002205A patent/CL2024002205A1/es unknown
- 2024-07-22 DO DO2024000142A patent/DOP2024000142A/es unknown
- 2024-07-24 JO JOJO/P/2024/0165A patent/JOP20240165A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025504859A5 (https=) | ||
| JP2024541929A5 (https=) | ||
| JP2024521878A5 (https=) | ||
| CN109863140B (zh) | 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺 | |
| JP2018505898A5 (https=) | ||
| JP2016529238A (ja) | 補体因子ｄ阻害剤としてのアミノメチル−ビアリール誘導体およびその使用 | |
| JP2016531134A5 (https=) | ||
| JP2021501790A5 (https=) | ||
| JP2019520417A5 (https=) | ||
| JP2021501789A5 (https=) | ||
| JP2021501786A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| JP2020518581A5 (https=) | ||
| CN112839945A (zh) | 补体因子d抑制剂的形态形式 | |
| JP2021501787A5 (https=) | ||
| CN105849090A (zh) | 2-苄基-苯并咪唑补体因子b抑制剂及其用途 | |
| JP2021501151A5 (https=) | ||
| JP2023523770A5 (https=) | ||
| EP3846803A2 (en) | Macrocyclic compounds for the treatment of medical disorders | |
| JP2013542267A5 (https=) | ||
| JP2022509206A5 (https=) | ||
| JP2022534902A (ja) | Ｂａｘ阻害剤およびその使用 | |
| JP2023507569A5 (https=) | ||
| JP2023515073A5 (https=) | ||
| JP2023515073A (ja) | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |